Table 1. Summary of articles included in the meta-analysis.
| Study | Country | Outcome | Study design | Age | Gender | case | control | |||||||||
| Males/Females | No | Yes | No | Yes | ||||||||||||
| PTGS1 rs3842787 | CT+TT/CC | CT+TT/CC | CT+TT/CC | CT+TT/CC | ||||||||||||
| Hubner et al, 2007 [4] | UK | CRA | cohort study | 57.3 ± 9.3 | 289/256 | 8/66 | 8/55 | 20/186 | 30/173 | |||||||
| Gallicchio et al, 2006 [5] | USA | BC | cohort study | 53.2 | 0/1467 (females only) | 10/55 | 2/13 | 136/770 | 51/305 | |||||||
| Ulrich et al, 2004 [6] | USA | CRA | case-control study | 30-74 | Without details | 41/287 | 29/190 | 56/288 | 38/273 | |||||||
| PTGS2 rs5275 | TC+CC/ TT | TC+CC/ TT | TC+CC/ TT | TC+CC/ TT | ||||||||||||
| Lurie et al, 2010 [7] | USA | OC | case-control study | ≥18 | 0/2454 (females only) | 300/282 | 194/172 | 452/375 | 344/361 | |||||||
| Andersen et al, 2009 [8] | Denmark | CRC | cohort study | 50-64 | 619/505 | 151/94 | 61/53 | 306/222 | 144/93 | |||||||
| Barry et al, 2009 [9] | USA | CRA | cohort study | 57.6 ± 9.6 | 630/349 | 81/72 | 156/118 | 103/70 | 200/163 | |||||||
| Gong et al, 2009 [10] | USA | CRA | case-control study | 30-74 | 168/205 | 84/50 | 14/14 | 96/54 | 46/15 | |||||||
| Vogel et al, 2008 [11] | Denmark | LC | nested case-cohort study | 50-64 | 631/516 | 151/125 | 69/54 | 290/218 | 139/90 | |||||||
| Vogel et al, 2007 [12] | Denmark | BCC | nested case-cohort study | 50-64 | 293/326 | 131/92 | 49/29 | 120/97 | 49/46 | |||||||
| Vogel et al, 2006 [13] | Denmark | BC | nested case-cohort study | 50-64 | 0/712 (females only) | 83/73 | 108/92 | 84/50 | 119/103 | |||||||
| Gallicchio et al, 2006 [5] | USA | BC | cohort study | 53.2 | 0/1467 (females only) | 37/29 | 5/9 | 511/396 | 198/158 | |||||||
| PTGS2 rs20417 | GC+CC/GG | GC+CC/GG | GC+CC/GG | GC+CC/GG | ||||||||||||
| Daraei et al, 2012 [14] | Iran | CRC | case-control study | 58.2±14.8 | 117/113 | 64/31 | 8/7 | 47/44 | 19/10 | |||||||
| Andersen et al, 2009 [8] | Denmark | CRC | cohort study | 50–64 | 619/505 | 65/180 | 27/87 | 131/397 | 68/169 | |||||||
| Barry et al, 2009 [9] | USA | CRA | cohort study | 57.6±9.6 | 630/349 | 40/109 | 86/181 | 47/117 | 97/263 | |||||||
| Gong et al, 2009 [10] | USA | CRA | case-control study | 30–74 | 168/205 | 45/89 | 9/19 | 60/90 | 24/37 | |||||||
| Hubner et al, 2007 [4] | UK | CRA | cohort study | 57.3±9.3 | 289/256 | 19/55 | 19/44 | 49/157 | 49/154 | |||||||
| Vogel et al, 2007 [12] | Denmark | BCC | nested case-cohort study | 50–64 | 293/326 | 59/164 | 25/53 | 49/168 | 23/72 | |||||||
| Ulrich et al, 2005 [15] | USA | CRA | case-control study | 30–74 | Without details | 95/217 | 64/127 | 96/228 | 83/177 | |||||||
| PTGS2 rs689466 | AG+GG/AA | AG+GG/AA | AG+GG/AA | AG+GG/AA | ||||||||||||
| Andersen et al, 2009 [8] | Denmark | CRC | cohort study | 50–64 | 619/505 | 89/156 | 40/74 | 199/329 | 84/153 | |||||||
| Vogel et al, 2008 [11] | Denmark | LC | nested case-cohort study | 50–64 | 631/516 | 90/186 | 49/74 | 194/314 | 81/148 | |||||||
| Vogel et al, 2007 [12] | Denmark | BCC | nested case-cohort study | 50–64 | 293/326 | 79/144 | 25/53 | 91/126 | 42/53 | |||||||
| PTGS2 rs2745557 | GA+AA/GG | GA+AA/GG | GA+AA/GG | GA+AA/GG | ||||||||||||
| Barry et al, 2009 [9] | USA | CRA | cohort study | 57.6±9.6 | 630/349 | 50/105 | 89/187 | 59/113 | 114/255 | |||||||
| Cheng et al, 2007 [16] | USA | PC | case-control study | Without details | 1337/0 (males only) | 64/264 | 78/413 | 80/144 | 108/186 | |||||||
| Gallicchio et al, 2006 [5] | USA | BC | cohort study | 53.2 | 0/1467 (females only) | 19/50 | 8/10 | 306/631 | 123/239 | |||||||
Abbreviations: No, non-NSAID users; Yes, NSAID users; PC, prostate cancer; CRC, colorectal cancer; OC, ovarian cancer; CRA, colorectal adenoma; LC, lung cancer; BCC, basal cell carcinoma; BC, breast cancer.